NCT00422032View on ClinicalTrials.gov

2 Arm Study of Clofarabine IV in MDS Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Myelodysplastic SyndromeLeukemia
Interventions
DRUG

Clofarabine

"Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days"

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00422032 - 2 Arm Study of Clofarabine IV in MDS Patients | Biotech Hunter | Biotech Hunter